Table 3.

HRs and 95% confidence intervals (CI) for colorectal cancer–specific death in relation to tumor composite scores for CTLs and GZMB in the colorectal cancer patients, IWHS, 1986–2011

CRC-specific death
Composite scoreNo. of deathsbPerson-yearsHR (95% CI)cHR (95% CI)dHR (95% CI)eHR (95% CI)f
CTLan = 144
2–3.850745ReferenceReferenceReferenceReference
4–5.1501,0890.73 (0.49–1.08)0.63 (0.42–0.94)0.67 (0.43–1.04)0.68 (0.45–1.02)
5.2–6.3231,0400.36 (0.22–0.59)0.41 (0.25–0.67)0.40 (0.23–0.72)0.49 (0.29–0.82)
>6.3211,0170.33 (0.20–0.55)0.30 (0.18–0.51)0.30 (0.15–0.57)0.44 (0.23–084)
Ptrend<0.0001<0.0001<0.00010.003
GZMBan = 144
2831,518ReferenceReferenceReferenceReference
2.2–2.8467440.71 (0.47–1.08)0.79 (0.52–1.21)0.69 (0.43–0.10)0.86 (0.56–1.33)
>3151,5440.37 (0.25–0.56)0.41 (0.27–0.63)0.44 (0.26–0.75)0.60 (0.35–1.03)
Ptrend0.0001<0.00010.0020.06
Joint score for CTL and GZMBgn = 144
040500ReferenceReferenceReference
1872,4430.48 (0.33–0.71)0.55 (0.37–0.79)0.59 (0.39–0.89)
2178250.27 (0.15–0.48)0.27 (0.15–0.49)0.27 (0.13–0.54)
Ptrend<0.0001<0.00010.0001
  • aTumor CTL and GZMB composite scores were created as a sum of corresponding epithelial and stromal scores categorized into quartiles for CTL and tertiles for GZMB.

  • bThe number of deaths is slightly different in the analyses of CTL and GZMB because of different number of available cores (n = 465 for CTL and n = 458 for GZMB; overall 468 colorectal cancer patients had tissues immunostained for CTL or GZMB).

  • cModel 1: Unadjusted.

  • dModel 2: Model adjusted for age at diagnosis, BMI, smoking status, stage, and grade at diagnosis.

  • eModel 3: Model 2 + integrated pathway.

  • fBoth GZMB and CTL tumor composite scores were included in addition to all the variables in Model 2.

  • gJoint score for GZMB and CTL tumor composite scores was created as follows: 0, lowest categories of CTL and GZMB; 2, highest categories of CTL and GZMB; and 1, all other combinations.